BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.358
+0.014 (4.07%)
At close: Jan 21, 2025, 4:00 PM
0.360
+0.002 (0.56%)
After-hours: Jan 21, 2025, 7:37 PM EST
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -86.07% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for BTAI stock have an average target of 2.81, with a low estimate of 0.25 and a high estimate of 5.00. The average target predicts an increase of 684.92% from the current stock price of 0.36.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BTAI stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $0.25 | Strong Buy → Sell | Downgrades | $7 → $0.25 | -30.17% | Jan 7, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +1,296.65% | Jan 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +1,296.65% | Oct 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,855.31% | Sep 6, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +1,855.31% | Aug 30, 2024 |
Financial Forecast
Revenue This Year
3.19M
from 1.38M
Increased by 131.45%
Revenue Next Year
4.65M
from 3.19M
Increased by 45.65%
EPS This Year
-1.86
from -6.15
EPS Next Year
-1.59
from -1.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 5.6M | 7.4M | 26.3M | |||
| Avg | 3.2M | 4.7M | 15.5M | |||
| Low | 2.2M | 1.5M | 4.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 308.6% | 130.1% | 464.3% | |||
| Avg | 131.4% | 45.6% | 232.9% | |||
| Low | 56.2% | -54.0% | 1.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.60 | -1.09 | -0.80 | |||
| Avg | -1.86 | -1.59 | -1.13 | |||
| Low | -2.34 | -2.00 | -1.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.